Enliven Therapeutics CMO Helen Louise Collins reports disposal of 5,000 common shares worth $293,612.17 - ELVN News | RalliesEnliven Therapeutics CMO Helen Louise Collins reports disposal of 5,000 common shares worth $293,612.17
E
ELVN• Insider share sale and option exercise
- Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 on Aug. 17, 2026.
- She sold 5,000 shares the same day in two transactions at weighted average prices of $58.37 and $59.35.
- Directly held common stock position stood at 25,000 shares following the transactions.
- Directly held stock options totaled 111,268 following the exercise.
TBLD
•
